Metrics as of 10/17/2026, 08:01 AM (Berlin time), refresh in progress.
Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals Incorporated
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Todd C. Davis
- Employees
- 47
- Market cap
- $5.9 B
- IPO
- 18/11/1992
Ligand Pharmaceuticals Incorporated is a healthcare company operating in the biotechnology sector. Headquartered in Jupiter, US, the company was established in 1987 and operates as a biopharmaceutical entity focused on sourcing and advancing technologies that empower pharmaceutical companies globally to discover and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Ligand Pharmaceuticals stock: price history
1D
-1.0%
1W
-2.1%
1M
+7.4%
6M
+27.5%
YTD
+56.3%
1Y
+63.5%
2Y
+175.8%
5Y
+263.7%
10Y
+408.7%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~33% stronger price swings than usual
Ligand Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
The Company operates a biopharmaceutical business model primarily based on licensing technologies and collecting royalty payments. A substantial portion of revenue is generated through participation in the sales of other pharmaceutical companies that utilize Ligand's proprietary technologies or formulations. Additionally, the Company is engaged in the sale of specialized materials such as Captisol and in the direct commercialization of various therapeutic solutions for indications in oncology, infectious diseases, and bone health.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Network effects
- Capital intensity
- Low
- Customer concentration
- Unknown
Ask the agents about Ligand Pharmaceuticals
Analyst assessment of Ligand Pharmaceuticals
PRICE TARGET LOW
US$326.00
CONSENSUS
US$339.43
MEDIAN
US$340.00
PRICE TARGET HIGH
US$358.00
0
STRONG BUY
13
BUY
4
HOLD
1
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 24/09/2026
Ligand Pharmaceuticals stock metrics
P/E
29.52
P/B
6.13
EV/EBITDA
21.96
RETURN ON EQUITY
5.0%
NET MARGIN
76.2%
DEBT/EQUITY
1.17
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.8%
FLOAT SHARES
19,489,251
AVG. DAILY VOLUME (30D)
253,772
Insider transactions (SEC)
Reardon Andrew
Reardon Andrew
Reardon Andrew
Reardon Andrew
Reardon Andrew
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Ligand Pharmaceuticals stock
What does Ligand Pharmaceuticals do?
Ligand Pharmaceuticals Incorporated is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Todd C. Davis, the company employs around 47 people.
The IPO was on 18/11/1992; the stock trades on NASDAQ under the ticker LGND.
What do analysts say about Ligand Pharmaceuticals stock?
18 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$339.43, ranging from US$326.00 to US$358.00, with a median of US$340.00.
This is an external assessment, not a statement by Market Jury.
When does Ligand Pharmaceuticals report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 33% stronger than usual.
Does Ligand Pharmaceuticals pay a dividend?
Yes. The last dividend was US$0.12 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Ligand Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Ligand Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ligand Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.